中国肺癌杂志2017，Vol.20Issue(2)：138-142,5.DOI:10.3779/j.issn.1009-3419.2017.02.09
PD-1/PD-L1抑制剂在晚期非小细胞肺癌中的治疗进展
Progress of PD-1/PD-L1 Inhibitors in Non-small Cell Lung Cancer
姜战胜1
作者信息
- 1. 300060 天津，天津医科大学肿瘤医院，国家肿瘤临床医学研究中心，天津市“肿瘤防治”重点实验室，天津市恶性肿瘤临床医学研究中心，天津市肿瘤免疫与生物治疗重点实验室，中西医结合科
- 折叠
摘要
Abstract
Pembrolizumab, an inhibitor target programmed death 1 (PD-1), was approved into the first line therapy in advanced non-small cell lung cancer (NSCLC). It was a milestone that immune checkpoints drugs have played an important role in the treatment system of NSCLC. The results of clinical trials revealed the superiority of PD-1/programmed death ligand 1 (PD-L1) inhibitors compared with chemotherapy in first-line, second-line and multidrug resistance phase therapy. Objective response rate (ORR) was up to 80% with pembrolizumab plus chemotherapy, and progression-free survival (PFS) with single pembrolizumab in first line was nearly 1 year (10.3 months), the hazard ratio for death fell by 40%. Overall survival (OS) was more or less 1 year with single drug pembrolizumab, nivolumab and atezolizumab for second line therapy. PD-L1 expression was a predictor of PD-1/PD-L1 inhibitors. The positive rate of PD-L1 (more than 1%) in advanced NSCLC was about 60% with little difference between the tissue types. However, there was no gold standard test of PD-L1 expression.关键词
肺肿瘤/程序性死亡受体1/程序性死亡配体1Key words
Lung neoplasms/Programmed death 1/Programmed death 1引用本文复制引用
姜战胜..PD-1/PD-L1抑制剂在晚期非小细胞肺癌中的治疗进展[J].中国肺癌杂志,2017,20(2):138-142,5.
